01:10 , Jun 26, 2019 |  BC Extra  |  Company News

AbbVie chooses revenue over innovation with Allergan takeout

Six years after splitting from Abbott to pursue innovative drug development, AbbVie has taken a clear about-face, choosing a certain immediate revenue stream in its proposed acquisition of Allergan rather than opting for a riskier,...
23:45 , Jun 19, 2019 |  BC Extra  |  Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
00:11 , Jun 14, 2019 |  BC Extra  |  Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

Roche's Gazyva clears Phase II hurdle in lupus nephritis  Gazyva obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) met the primary endpoint in the Phase II NOBILITY trial to treat lupus nephritis. Given in combination with standard of...
00:20 , Jun 11, 2019 |  BC Extra  |  Clinical News

June 10 Clinical Quick Takes: Oral semaglutide superior to Jardiance, non-inferior to Victoza; plus Aptinyx and Eli Lilly

Novo’s oral semaglutide meets in Phase III trials  Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported results from two Phase III trials of its oral semaglutide in Type II diabetes. In PIONEER 2, oral semaglutide, a...
22:01 , Jun 10, 2019 |  BC Extra  |  Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...
21:50 , Jun 5, 2019 |  BC Extra  |  Financial News

Oncolytic virus play OncoMyx raises $25M series A

Arizona State University spinout OncoMyx raised $25 million in a series A round to develop its oncolytic virus programs in solid cancers. Boehringer Ingelheim Venture Fund, Delos Capital and Xeraya Capital co-led the tranched financing....
23:46 , Jun 4, 2019 |  BC Extra  |  Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches  FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for...
21:31 , May 28, 2019 |  BC Extra  |  Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

A licensing deal with Lilly for an analgesic will bolster Centrexion's balance sheet six months after it canceled plans for an IPO. Centrexion will receive $47.5 million up front and is eligible for $950 million...
17:56 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat acute ischemic stroke. In two mouse models of ischemic stroke, the combination of the ADRA1 antagonist prazosin, the ADRA2...